A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Ustekinumab (Primary) ; Golimumab
- Indications Spondylarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 11 Aug 2017 Planned End Date changed from 22 May 2019 to 16 Aug 2017.
- 11 Aug 2017 Planned primary completion date changed from 19 Aug 2018 to 16 Aug 2017.
- 27 Jul 2017 This trial has been completed in Portugal (end date: 2017-05-17).